Valeric acid
|
Basic information |
| Metabolite name | Valeric acid |
 | HMDB0000892 |
 |
C00803 |
 |
7991 |
| Synonyms | Pentanoic acid; |
| No. of studies | 23 |
|
Basic information |
| Metabolite name | Valeric acid |
| HMDB0000892 |
|
C00803 |
|
7991 |
| Synonyms | Pentanoic acid; |
| No. of studies | 23 |
|
Relationship between Valeric acid and depression (count: 23) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M074 | Type1 | sCSDS group vs. control group | Faece | C57BL/6JJmsSlc mouse | Up |
| Study M1002 | Type2 | high-fat diet + Xiaoyao San group vs. high-fat diet group | Faece | C57Bl6/J mouse | Up |
| Study M1003 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M1003 | Type2 | CUMS + Morinda officinalis oligosaccharide group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1009 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1009 | Type2 | CUMS + multi-probiotics group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M1017 | Type1 | post-stroke depression group vs. control group | Serum | C57BL/6j mouse | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1025 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Down |
| Study M1087 | Type1 | CSDS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M665 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M706 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M731 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M804 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M804 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M804 | Type2 | CUMS + middle dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M804 | Type2 | CUMS + high dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M872 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M886 | Type2 | lead-exposed + probiotics group vs. lead-exposed group | Faece | Sprague-Dawley rat | Up |
| Study M900 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M900 | Type2 | CUMS + Semen Sojae Praeparatum group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M956 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M956 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Up |
| Study M985 | Type2 | CUMS + indole acetic acid group vs. CUMS group | Cecum | C57BL/6J mouse | Up |
| Study M990 | Type1 | aged microbiota transplant group vs. young microbiota transplant group | Faece | C57BL/6 mouse | Up |
| Study M999 | Type2 | CRS + high dose of neoagaro-oligosaccharides group vs. CRS group | Faece | C57BL/6J mouse | Up |
| Study M999 | Type2 | CRS + low dose of neoagaro-oligosaccharides group vs. CRS group | Faece | C57BL/6J mouse | Up |
| Study M999 | Type2 | CRS + paroxetine group vs. CRS group | Faece | C57BL/6J mouse | Up |